Specific Biologics is an early-stage biotechnology company on a mission to develop novel gene editing technologies to treat diseases through precision gene editing
Trending at Lumira Ventures
Swift Medical is a leader in imaging technology and data analytics solutions for the healthcare industry. Swift Wound, together with Swift’s Metrics dashboard, represents a new generation in wound care management technology.
XyloCor Therapeutics is a biopharmaceutical company focused on the development of novel gene therapy for unmet needs in advanced coronary artery disease.
Aurinia Pharmaceuticals lead drug, LUPKYNIS (voclosporin), was approved in January 2021 as the first oral therapy for lupus nephritis, a condition that causes irreversible kidney damage and increases the risk of kidney failure, cardiac events, and death
Bardy Diagnostics, an innovator in digital health and remote patient monitoring, with a focus on providing the most diagnostically-accurate and patient-friendly cardiac patch and other monitors to the industry was acquired by Hillrom for $375 million in January 2021
Engage Therapeutics is focused on epilepsy patients suffering from uncontrolled seizures with what could be the first rescue treatment with the potential to stop their seizures. The company was acquired by UBC for up to US$270 million in June 2020. …
Essa Pharmaceuticals is a clinical stage company developing a small molecule therapy to overcome the issue of drug resistance for patients with prostate cancer.
Forbius is a clinical stage company that designs and develops biotherapeutics for treatment of cancer and fibrosis. The company was acquired by Bristol Myers Squibb in August 2020.
Lumira was an early investor in MAKO Surgical Corp. prior to its IPO and later when it was acquired by Stryker for $1.65 billion in 2013 for its minimally invasive robotic surgical arm for partial knee and total hip arthroplasty.
Pharmasset was acquired by Gilead in 2011 for $11 billion for their oral therapeutics for the treatment of hepatitis C virus (HCV) and human immunodeficiency virus (HIV).
Zymeworks is a biotherapeutics company that is developing best-in-class Azymetric™ bi-specific antibodies and antibody drug conjugates for the treatment of cancer, autoimmune and inflammatory diseases.
Alveolus, developer of next generation non-vascular interventional stent technology for use in the lungs, was acquired by Merit Medical Systems Inc. in February 2008.
Ception Therapeutics was acquired by Cephalon Inc. in March 2010 in a deal worth $350 million plus significant future millstones. Cephalon Inc. was subsequently acquired by Teva in 2011.
Corus Pharmaceuticals, developer of Aztreonam for treatment of cystic fibrosis and Lidocaine for treatment of oral corticosteroid dependent asthma, was acquired by Gilead in August 2006 for $365 million.
Lumira Ventures led a PIPE in Depomed in 2003 and fully exited in 2006 after the FDA approved the company’s two lead products in 2005.